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Abstract
Marfan syndrome (MFS) is caused by mutations in the fibrillin-1 (FBN1) gene, and mutations in FBN1 are known to
be responsible for over 90% of all MFS cases. Locus heterogeneity has also been reported and confirmed, with
mutations in the receptor genes TGFBR1 and TGFBR2 identified in association with MFS-related phenotypes. It is
now known that dysregulation of TGF-ß signaling is involved in MFS pathogenesis. To test the hypothesis that
dysregulation of TGFBR3-associated TGF-ß signaling is implicated in MFS or related phenotype pathogenesis, we
selected a cohort of 49 patients, fulfilling or nearly fulfilling the diagnostic criteria for MFS. The patients were
known not to carry a mutation in the FBN1 gene (including three 5’ upstream alternatively spliced exons), the
TGFBR1 and TGFBR2 genes. Mutation screening for the TGFBR3 gene in these patients and in controls led to the
identification of a total of ten exonic (one novel), four intronic (one novel) and one 3’UTR variant in the TGFBR3
gene. Our data suggest that variations in TGFBR3 gene appear not to be associated with MFS or related
phenotype.
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Background
Marfan syndrome (MFS; MIM# 154700) is an autoso-
mal-dominant disorder of connective tissue with major
manifestations in the skeletal, cardiovascular and ocular
systems. MFS is caused by mutations in the fibrillin-1
gene (FBN1), and mutations in FBN1 are known to be
responsible for over 90% of all MFS cases. However,
locus heterogeneity was reported in the early 1990’s,
when a second locus 3p24.2-p25 was suggested to cause
MFS [1]. This association was further confirmed when
mutations were identified in the transforming growth
factor ß receptor type II gene (TGFBR2), which maps to
the corresponding chromosomal region, in patients with
overlapping phenotypes of MFS and Loeys-Dietz syn-
drome (LDS1B; MIM#610168) [2-4]. Later, using a func-
tional approach, mutations were identified in another
receptor of TGF-ß receptor family, transforming growth
factor ß receptor type I (TGFBR1)i na s s o c i a t i o nw i t h
MFS or related phenotypes LDS (LDS1A; MIM#609192)
[3-5]. These and other findings, strongly suggested an
important role played by TGF-ß receptors and TGF-ß
signaling dysregulation in the pathogenesis of MFS and
related phenotypes [6,7]. The TGF-ß signaling pathway
regulates extracellular matrix formation through mem-
bers of the TGF-ß superfamily and their receptors [8].
TGF-ß mainly functions by binding to three cell surface
receptors, namely TGFBR1 (55 kD), TGFBR2 (80 kD)
and transforming growth factor receptor type III
(TGFBR3, 280 kD) [9]. TGFBR3 is the most abundantly
expressed subtype, has high affinity for all three TGF-ß
isoforms, and acts as an enhancer of the TGF-ß access
to the other signaling receptors [10]. So far, no systema-
tic search for TGFBR3 genetic variation associated with
MFS and related phenotypes has been reported in the
literature. To test the hypothesis that dysregulation of
TGFBR3-associated TGF-ß signaling is implicated in
MFS or related phenotype pathogenesis, we selected a
cohort of 49 patients, fulfilling or nearly fulfilling the
diagnostic criteria for MFS. The patients were known
not to carry a mutation in the FBN1 gene (including
three 5’ upstream alternatively spliced exons), the
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TGFBR3 gene in these patients and in controls led to
the identification of a total of ten exonic (one novel),
four intronic (one novel) and a 3’UTR variant in the
TGFBR3 gene. Our data suggest that variations in
TGFBR3 gene appear not to be associated with MFS or
related phenotype.
Results and Discussion
In a cohort of 49 unrelated probands with the tentative
diagnosis of Marfan syndrome or fulfilling criteria of the
“revised Ghent nosology” of 1996 [11] without identified
mutation in the FBN1, TGFBR2,a n dTGFBR1 coding
regions, a systematic mutation screen was performed by
sequencing all 17 exons of TGFBR3 gene.At o t a lo ft e n
exonic (one novel), four intronic (one novel) and a
3’UTR sequence alterations were detected. Molecular
findings of all index patients and relatives carrying var-
iants in TGFBR3 gene are summarized in table 1.
Among the exonic variants identified; c.44C > T (p.
S15F; exon 2), c.216G > A (p. A72A; exon3), c.1128 (p.
I376I; exon 9), c.1206G > A (p.P402P; exon 9), c.1341C
> T (p.S447S; exon 9), c.2028C > T (p.F676F; exon 13)
and c.2247C > T (p.T749T; exon 14) were detected in
index patients in the same allele frequency as controls.
Bioinformatic analyses using the online-software Muta-
tion Taster, PMut and PolyPhen2 did not assign any dis-
ease-causing effect to these variants. Two already known
exonic variants c.2293G > C (p.G765R; exon 15) and
c.2329C > T (p.P777S; exon 15) were only detected in
two and one index cases respectively, but not in
controls. The first index case with the c.2293G > C var-
iant was a 17-year-old male, who fulfilled the Ghent
major criterion in the skeletal system, showed the invol-
vement of the cardiovascular system and had a negative
family history. The second index case with the c.2293G
> C variant was a male sporadic case with suspected
MFS and he was 26 years of age at the time of examina-
tion. The skeletal system was involved (body propor-
tions, positive thumb and wrist signs, scoliosis, highly
arched palate, typical facial features) and a major criter-
ion would have been fulfilled, if he had been tested posi-
tive for the presence of protusio acetabuli. He had
mitral valve prolapse. The variant c.2293G > C was pre-
sent in his mother, who had no signs of MFS, and was
absent in the healthy father.
The variant c.2329C > T was identified in a 14-year-
old boy with involvements of the skeletal system and
the skin. He had normal height at the age of 12-years, a
slight funnel chest, flat feet, positive thumb and wrist
signs, highly arched palate and joint hypermobility with
recurrent herniae. Further anomalies were hypodontia
(aplasia of 9 teeth), dysmorphic ears and stenosis of the
external auditory meatus. At the age of 13-years celiac
disease was diagnosed. His parents did not have signs of
MFS, his mother was hypodontic but we were unable to
screen the mother for the presence of this variant. This
variant was identified in the healthy father.
The online-program PMut predicted both variants,
c.2293G > C and c.2329C > T to be possibly pathogenic.
On the contrary, the online-software Mutation Taster
and PolyPhen2 did not assign any disease-causing effect
Table 1 Variants identified and their respective allele frequencies in the TGFBR3 gene
Variants Location Amino Acid Allele freq. Patient (n = 49) Allele freq. Controls Ref. Acc. Nr. Allele freq.
c.44C > T Exon 2 S15F 0.11 0.12 (n = 54) rs1805110 0.325
c.55A > G Exon 2 T19A 0.02 0.00 (n = 54) Novel
c.62-51 C > T Intron 2 0.01 0.03 (n = 52) rs17881268 0.03
c.216G > A Exon 3 A72A 0.32 0.35 (n = 52) rs2810904 0.407
c.247-40C > T Intron 3 0.18 0.13 (n = 45) rs11165441 0.13
c.886-1 0A > G Intron 7 0.01 0.00 (n = 40) Novel
c.1128C > T Exon 9 I376I 0.01 0.00 (n = 55) rs11466595 0.015
c.1206G > A Exon 9 P402P 0.41 0.41 (n = 55) rs1805112 0.477
c.1341C > T Exon 9 S447S 0.02 0.02 (n = 55) rs2229500 ND
c.1566 + 55C > A Intron 10 0.26 0.28 (n = 58) rs7524066 0.19
c.2028C > T Exon 13 F676F 0.51 0.41 (n = 59) rs1805113 0.417
c.2247C > T Exon 14 T749T 0.07 0.07 (n = 50) rs284878 0.196
c.2293G > C Exon 15 G765R 0.02 0.00 (n = 50) rs17882828 0.034
c.2329C > T Exon 15 P777S 0.01 0.00 (n = 50) rs35352606 0.01
c.*19G > A 3’UTR 0.13 0.25 (n = 52) rs1131243 0.10
The numbering is based on the mRNA sequence (TGFBR3; accession number NM_003243.4), where 1 corresponds to the nucleotide A of ATG, the translation
initiation codon.
ND; not yet determined.
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into account, both variants are apparently not disease-
causing.
In our cohort, we encountered three known and one
novel intronic variant in the TGFBR3 gene. Three
known intronic variants c.62-51C > T (intron 2), c.247-
40C > T (intron 3) and c.1566 + 55C > A (intron 10)
along with 3’UTR variant (c.*19G > A) occurred in the
index cases in the same allele frequency as in control
cases. However, intronic variant c.886-10A > G (intron
7) is novel and was identified in a MFS case, who was
later confirmed to carry a FBN1 mutation. Bioinformatic
analyses using the online-programs Mutation Taster,
Fruitfly and NetGene2 Server did not assign any dis-
ease-causing effect to these variants.
The only novel exonic variant c.55A > G (p.T19A;
exon 2) was identified in two index cases with positive
family history. The first index case was a 34-year-old
male with marfanoid habitus and aortic aneurysm. The
affected maternal uncle of this index case who also had
Marfanoid habitus and aortic aneurysm, was wild type
for c.55A > G but carried another variant c.44C > T (p.
S15F; exon 2). The mother of the index patient had a
marfanoid habitus as the only symptom of MFS and did
not carry c.55A > G. A healthy sister of the index case
carried c.55A > G and the son of the deceased daughter
of the maternal uncle did not carry c.55A > G.
Another index patient with c.55A > G was a 40-year-
old female with a mild dilatation of the aortic root (3.5
cm), when she was a young adult. As the dilatation was
not progressive, the diameter of the aortic root was in
the normal range when she got older. She had skeletal
involvement (arm-span to height ratio >1.05, positive
thumb and wrist signs, flat feet, highly arched palate)
and had a history of two spontaneous pneumothoraxes.
She had frequent nasal bleeding and easy bruising with-
out trauma or varicosis. The affected daughter, who car-
ried variant c.55A > G was 8 years of age when
examined and had a dilatation of the aortic root with a
diameter of 2.5 cm. Skeletal system was involved (posi-
tive thumb and wrist signs, flat feet and joint hypermo-
bility). Additionally she had muscular hypotonia. A
healthy son, brother and the mother of the index patient
c.55A>G
c.44C
c.55A>G
c.44C
na
c.55A>G
c.44C
c.55A>G
c.44C>T
c.55A
c.44C
c.55A
c.44C
c.55A>G
c.44C>T
c.55A
c.44C>T
Figure 1 Pedigree of a family with Marfan syndrome associated with c.44C > T (p.S15F) and c.55A > G (p.T19A) in the TGFBR3 gene.
The Index patient is indicated by arrow. na: no DNA available.
Table 2 Amino acid sequence comparison (44C > T; S15F
and 55A > G; T19A) of the highly conserved TGFBR3
signal domain from Homo sapiens (accession no.
NP_003234.2), Pan troglodytes (accession no.
XP_513555.2), Sus scrofa (accession no. NP_999437.1),
Mus musculus (accession no. NP_035708) and Rattus
norvegicus (accession no. NP_058952.1)
Species Amino acid sequence
H. sapiens SCLATAGPEP
P. troglodytes SCLATAGPEP
M. mulatta SCLATAGPEP
S. scrofa SCLATAGPEP
M. musculus ACLATAGPEP
R. norvegicus ACLATAGPEP
Amino acid residues found to show variation as identified in this study are
highlighted in bold and respective conserved amino acids are shown in bold
and underlined.
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patient carried another variant c.44C > T as well. Two
other healthy brothers and the husband did not carry
the c.55A > G variant, but the husband carried the
c.44C > T variant (figure 1). Both of these exonic var-
iants occurred in a highly conserved TGFBR3 signal
domain (table 2). A possible interpretation of c.55A >
G; T19A is that it may be a predisposing factor to the
aortic dilatation, as it affects a highly conserved signal
domain (http://www.uniprot.org/uniprot/Q03167) and
plausibly could affect the function of TGFBR3. c.55A >
G; T19A may thus act as a mutation with reduced pene-
trance or perhaps as a variant that in combination with
variation in other genes could lead to aortic dilatation.
The bioinformatic prediction tool (http://www.cbs.dtu.
dk/services/SignalP/) showed, however, that both c.55A
> G sequences were predicted to be a valid signal
sequences.
Conclusions
Taken together our data demonstrate that at least in our
cohort, variations in TGFBR3 gene do not appear to
play a role in the aetiology of MFS or related pheno-
types, although the role of TGFBR3 variants as a genetic
modifier can not be ruled out. Identification of known
and novel variants in the current study could be useful
in the studies of the other related disease
aetiopathogeneses.
Materials and Methods
Probands
49 unrelated individuals used in this study had been
referred between 1997 and 2005 to our clinic or genetic
testing service with suspected Marfan syndrome or ful-
filling Ghent diagnostic criteria of Marfan syndrome.
These patients, had already been screened for 65 along
with additionally three 5’ alternatively spliced exons of
FBN1 gene, 8 exons of TGFBR2 gene, and all 9 exons of
TGFBR1 gene as described before [11-14] and were
found not to carry a disease-causing mutation. Blood
samples were taken and genomic DNA was extracted
using standard protocols. Primers were designed based
on the human sequence (accession number
AY796304.1) for all 17 exons of TGFBR3 gene (table 3).
To analyse the exonic variants we used the bioinfor-
matic prediction programs Mutation Taster (http://
www.mutationtaster.org/), PMut (http://mmb2.pcb.ub.
es:8080/PMut/) and PolyPhen2 (http://genetics.bwh.har-
vard.edu/pph2/). All intronic variants and the variant in
the 3’UTR were analysed with Mutation Taster (http://
www.mutationtaster.org/), Berkeley Drosophila Genome
Project “Splice Site Prediction” (http://www.fruitfly.org/
seq_tools/splice.html) and NetGene2 Server (http://
www.cbs.dtu.dk/services/NetGene2/). Patients carrying
TGFBR3 variants were re-contacted in order to be
checked for MFS, LDS related and/or additional
symptoms.
PCR and DNA Sequencing
Standard PCR conditions were initial denaturation at 95°
C for 10 min followed by 33 cycles of 96°C for 1 min,
55°C for 1 min and 72°C for 1 min with final elongation
for 10 min at 72°C in a 50-μl reaction mixture, contain-
ing 1X buffer (Qiagen, Germany), 1X Q solution (Qia-
gen, Germany), 20 pM each primer and 2.5U Taq
Polymerase (Qiagen, Germany). The annealing tempera-
ture for exon 1 and 15 were 65°C and 58°C, respectively.
Table 3 Sequences of primer pairs used for amplification
of all 17 exons and the 3’UTR of TGFBR3 gene
Name Primer sequences
Exon 1F 5’- AGG-GAG-GGC-GAG-TGC-GCC-GGG-T-3’
Exon 1R 5’- GGA-GGT-CCT-GGC-GGC-TGG-AGC-G-3’
CDS 1F 5’- GTC-TGT-GCT-CTG-AGC-AGC-CTG-AAG-3’
CDS 1R 5’- TCA-TCT-CAA-CTA-AAG-AGA-CTG-GGA-3’
CDS 2F 5’- GGC-ATC-TCT-GGT-GGG-TTG-GCA-GTG-3’
CDS 2R 5’- GCA-GAC-TCA-GTG-GCA-GTG-GGC-TGA-G-3’
CDS 3F 5’- GTA-TTC-CAG-AGG-CTG-CTC-TGA-G-3’
CDS 3R 5’- GAC-TCT-GGC-ATT-ATT-TCA-GTG-AAA-G-3’
CDS 4F 5’- CTT-CGA-TTT-GAG-AAG-TAC-TTT-CTC-T-3’
CDS 4R 5’- AAC-AAT-TGC-CTG-TCA-TAA-ATC-AGT-C-3’
CDS 5F 5’- GAA-TCT-GGT-TAC-CGA-GTA-CCT-CAG-3’
CDS 5R 5’- TCT-CCC-TGC-CTC-AAG-TCA-AGG-AAG-3’
CDS 6F 5’- GAC-ACT-AGA-AAC-ATG-AAG-ACT-TGG-3’
CDS 6R 5’- GAG-CTT-AGA-GAG-TCC-AAA-GAG-GCA-G-3’
CDS 7F 5’- CTA-AAG-TAC-TGT-TTA-ATT-TTA-GA-3’
CDS 7R 5’- CAT-ATA-AGC-TGA-AAT-GAC-AGT-TCC-3’
CDS 8F 5’- GTG-GCC-TGG-CAT-CAA-ACA-CTG-CTG-3’
CDS 8R 5’- CAG-ATG-CAG-ACT-AGG-GCC-AGA-TGG-3’
CDS 9F 5’- GTG-TCA-ATT-ATA-CAA-CAG-AAC-TGC-3’
CDS 9R 5’- CCC-TCT-TCA-TCT-TCA-AAG-AAA-TGT-T-3’
CDS 10F 5’- GAA-CCA-AAC-ACA-CAT-GGT-TTG-GTG-3’
CDS 10R 5’- GAT-AGT-CCC-TAA-CTA-AAG-CCA-ACA-A-3’
CDS 11F 5’- ATC-CTT-CAT-ATG-ACT-GTC-ATT-AAT-C-3’
CDS 11R 5’- GTA-TTT-TAG-CTG-ATG-TCT-AAG-GAA-C-3’
CDS 12F 5’- CCT-AAA-GTG-AAA-GTG-AGA-TGC-TAA-C-3’
CDS 12R 5’- CCT-CAC-CTA-AAA-ATG-CCA-AAA-TAA-C-3’
CDS 13F 5’- GTA-GAG-CTG-GTG-AAG-GCA-CTT-TTG-3’
CDS 13R 5’- GGT-CTT-CTT-AAC-AAG-CAG-AGC-TCA-G-3’
CDS 14F 5’- ATC-ATT-GAC-AGA-GCT-TTC-TCA-CAG-T-3’
CDS 14R 5’- GAA-TGA-GAG-CAG-AAG-TCT-CCT-TAT-C-3’
CDS 15F 5’- TGC-AAT-GCA-TGA-TGC-AGA-CTA-ACC-A-3’
CDS 15R 5’- ACA-AGC-TGT-TCA-CCA-ACT-CTT-ACT-C-3’
CDS 16F 5’- GGA-ATG-CAC-ATA-CAT-AAT-ATG-CGT-C-3’
CDS 16R 5’- GAA-TAC-AAC-GGG-TGA-TCT-TTA-TAC-3’
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USA), and both strands were sequenced with BigDye
Terminator chemistry version 1.1 by standard protocol
(ABI, USA). Sequencing reactions were carried out at
96°C for 10s, 50°C for 5s, and 60°C for 4 mins (25
cycles) (Biometra, Germany). The reaction mixtures
were purified using DyeEx™ 2.0 Spin Kit (Qiagen, Ger-
many) and analyzed on the ABI Genetic Analyser 3100
according to the supplier’s instructions with the
sequence analysis software (ABI, USA).
Controls
All sequence alterations were checked in a sample of 55
healthy control blood donors.
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